Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
- Christopher M. StephensonAffiliated withCancer Treatment Centers of America®
- , Robert D. LevinAffiliated withCancer Treatment Centers of America®
- , Thomas SpectorAffiliated withSpector Consulting Services
- , Christopher G. LisAffiliated withCancer Treatment Centers of America®Cancer Treatment Centers of America® Email author
This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy.
Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min for 4 consecutive days/week for 4 weeks, starting at 30 g/m2 in the first cohort. For subsequent cohorts, dose was increased by 20 g/m2 until a maximum tolerated dose was found.
Ascorbic acid was eliminated by simple first-order kinetics. Half-life and clearance values were similar for all patients of all cohorts (2.0 ± 0.6 h, 21 ± 5 dL/h m2, respectively). C max and AUC values increased proportionately with dose between 0 and 70 g/m2, but appeared to reach maximal values at 70 g/m2 (49 mM and 220 h mM, respectively). Doses of 70, 90, and 110 g/m2 maintained levels at or above 10–20 mM for 5–6 h. All doses were well tolerated. No patient demonstrated an objective antitumor response.
Ascorbic acid administered i.v. at 1 g/min for 4 consecutive days/week for 4 weeks produced up to 49 mM ascorbic acid in patient’s blood and was well tolerated. The recommended dose for future studies is 70–80 g/m2.
KeywordsAscorbic acid Cancer Pharmacokinetics Phase I clinical trial
- Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Cancer Chemotherapy and Pharmacology
Volume 72, Issue 1 , pp 139-146
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Ascorbic acid
- Phase I clinical trial
- Industry Sectors
- Author Affiliations
- 1. Cancer Treatment Centers of America®, 2520 Elisha Ave., Zion, IL, 60099, USA
- 3. Spector Consulting Services, 5216 Old Chapel Hill Road, Durham, NC, 27707, USA
- 2. Cancer Treatment Centers of America®, 1336 Basswood Road, Schaumburg, IL, 60173, USA